These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 22656409)

  • 1. Can conventional magnetic resonance imaging, prostate needle biopsy, or their combination predict the laterality of clinically localized prostate cancer?
    Jeong CW; Ku JH; Moon KC; Hong SK; Byun SS; Cho JY; Kim HH; Kim SH; Lee SE; Kwak C
    Urology; 2012 Jun; 79(6):1322-7. PubMed ID: 22656409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are prostate needle biopsies predictive of the laterality of significant cancer and positive surgical margins?
    Frota R; Stein RJ; Turna B; Kamoi K; Lin YC; Magi-Galluzzi C; Aron M; Gill IS
    BJU Int; 2009 Dec; 104(11):1599-603. PubMed ID: 19583724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diffusion-weighted magnetic resonance imaging in patients with unilateral prostate cancer on extended prostate biopsy: predictive accuracy of laterality and implications for hemi-ablative therapy.
    Jeong IG; Kim JK; Cho KS; You D; Song C; Hong JH; Ahn H; Kim CS
    J Urol; 2010 Nov; 184(5):1963-9. PubMed ID: 20851437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy.
    Polascik TJ; Mayes JM; Schroeck FR; Sun L; Madden JF; Moul JW; Mouraviev V
    Cancer; 2009 May; 115(10):2104-10. PubMed ID: 19288576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of diffusion-weighted magnetic resonance imaging and extended prostate biopsy predicts lobes without significant cancer: application in patient selection for hemiablative focal therapy.
    Matsuoka Y; Numao N; Saito K; Tanaka H; Kumagai J; Yoshida S; Koga F; Masuda H; Kawakami S; Fujii Y; Kihara K
    Eur Urol; 2014 Jan; 65(1):186-92. PubMed ID: 23084330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discrepancy in prostate cancer localization between biopsy and prostatectomy specimens in patients with unilateral positive biopsy: implications for focal therapy.
    Sinnott M; Falzarano SM; Hernandez AV; Jones JS; Klein EA; Zhou M; Magi-Galluzzi C
    Prostate; 2012 Aug; 72(11):1179-86. PubMed ID: 22161896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer?
    Tareen B; Godoy G; Sankin A; Temkin S; Lepor H; Taneja SS
    BJU Int; 2009 Jul; 104(2):195-9. PubMed ID: 19191784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
    Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
    Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
    J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of transrectal saturation biopsy in tumour localization: pathological correlation after retropubic radical prostatectomy and implication for focal ablative therapy.
    Abdollah F; Scattoni V; Raber M; Roscigno M; Briganti A; Suardi N; Gallina A; Capitanio U; Freschi M; Salonia A; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2011 Aug; 108(3):366-71. PubMed ID: 21087451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can the conventional sextant prostate biopsy accurately predict unilateral prostate cancer in low-risk, localized, prostate cancer?
    Mayes JM; Mouraviev V; Sun L; Tsivian M; Madden JF; Polascik TJ
    Urol Oncol; 2011; 29(2):166-70. PubMed ID: 19451000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phased array magnetic resonance imaging for staging clinically localised prostrate cancer.
    Borre M; Lundorf E; Marcussen N; Langkilde NC; Wolf H
    Acta Oncol; 2005; 44(6):589-92. PubMed ID: 16294442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increasing the number of biopsies increases the concordance of Gleason scores of needle biopsies and prostatectomy specimens.
    Divrik RT; Eroglu A; Sahin A; Zorlu F; Ozen H
    Urol Oncol; 2007; 25(5):376-82. PubMed ID: 17826653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
    Horiguchi A; Nakashima J; Horiguchi Y; Nakagawa K; Oya M; Ohigashi T; Marumo K; Murai M
    Prostate; 2003 Jun; 56(1):23-9. PubMed ID: 12746843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
    J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy.
    Graefen M; Haese A; Pichlmeier U; Hammerer PG; Noldus J; Butz K; Erbersdobler A; Henke RP; Michl U; Fernandez S; Huland H
    J Urol; 2001 Mar; 165(3):857-63. PubMed ID: 11176486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer detection by prebiopsy 3.0-Tesla magnetic resonance imaging.
    Nishida S; Kinoshita H; Mishima T; Kurokawa H; Sakaida N; Matsuda T
    Int J Urol; 2011 Sep; 18(9):653-8. PubMed ID: 21790792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection.
    Haffner J; Lemaitre L; Puech P; Haber GP; Leroy X; Jones JS; Villers A
    BJU Int; 2011 Oct; 108(8 Pt 2):E171-8. PubMed ID: 21426475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer.
    Yoshizako T; Wada A; Hayashi T; Uchida K; Sumura M; Uchida N; Kitagaki H; Igawa M
    Acta Radiol; 2008 Dec; 49(10):1207-13. PubMed ID: 19031184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.